SLNSW-Durvalumab with platinum-pemetrexed for unresecta...-TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Full title: Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Author/creator: Forde, Patrick M, Anagnostou, Valsamo, Sun, Zhuoxin, Dahlberg, Suzanne E, Kindler, Hedy L, Niknafs, Noushin, Purcell, Thomas, Santana-Davila, Rafael, Dudek, Arkadiusz Z, Borghaei, Hossein, Lanis, Mara, Belcaid, Zineb, Smith, Kellie N, Balan, Archana, White, James R, Cherry, Christopher, Ashok Sivakumar, I K, Shao, Xiaoshan M, Chan, Hok Yee, Singh, Dipika, Thapa, Sampriti, Illei, Peter B, Pardoll, Drew M, Karchin, Rachel, Velculescu, Victor E, Brahmer, Julie R, Ramalingam, Suresh S.

Call Numbers:

Record Identifier: TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

Language: English

Formats: Articles

Publishers: United States: Nature Publishing Group

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    Record identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

    Share

    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    Full title

    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    Author / Creator

    Forde, Patrick M ; Anagnostou, Valsamo ; Sun, Zhuoxin ; Dahlberg, Suzanne E ; Kindler, Hedy L ; Niknafs, Noushin ; Purcell, Thomas ; Santana-Davila, Rafael ; Dudek, Arkadiusz Z ; Borghaei, Hossein ; Lanis, Mara ; Belcaid, Zineb ; Smith, Kellie N ; Balan, Archana ; White, James R ; Cherry, Christopher ; Ashok Sivakumar, I K ; Shao, Xiaoshan M ; Chan, Hok Yee ; Singh, Dipika ; Thapa, Sampriti ; Illei, Peter B ; Pardoll, Drew M ; Karchin, Rachel ; Velculescu, Victor E ; Brahmer, Julie R ; Ramalingam, Suresh S

    Publisher

    United States: Nature Publishing Group

    Journal title

    Nature medicine, 2021, Vol.27 (11), p.1910-1920

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adult Adverse events Aged Aged, 80 and over Analysis Antibodies Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Cancer Cancer genomics Cancer immunotherapy Carboplatin - therapeutic use Care and treatment Chemotherapy Cisplatin Cisplatin - therapeutic use Deoxyribonucleic acid Diagnosis DNA DNA repair DNA Repair - genetics Dosage and administration Female Genetic Predisposition to Disease - genetics Genomic instability Germ-Line Mutation - genetics Histology Humans Immune checkpoint Immune system Immunogenicity Immunotherapy Lymphocytes Lymphocytes T Male Mesothelioma Mesothelioma, Malignant - drug therapy Mesothelioma, Malignant - genetics Mesothelioma, Malignant - mortality Methods Middle Aged Monoclonal antibodies Mutation Nucleic Acid Synthesis Inhibitors - adverse effects Nucleic Acid Synthesis Inhibitors - therapeutic use Patients PD-L1 protein Pemetrexed Pemetrexed - adverse effects Pemetrexed - therapeutic use Phase II trials Platinum Progression-Free Survival Radioimmunotherapy Risk factors Side effects Stability analysis Survival T cells Targeted cancer therapy Tumor Suppressor Proteins - genetics Tumors Tumour immunology Ubiquitin Thiolesterase - genetics

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604731

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections